What is Cyprotex?
Cyprotex operates as a specialized research organization dedicated to advancing pharmaceutical development through comprehensive preclinical analysis. The company provides essential scientific services that evaluate how potential drug candidates behave within biological systems, examining their absorption, distribution, metabolism, and pharmacokinetic properties. This expertise is fundamental for pharmaceutical companies aiming to understand drug behavior before clinical trials. Cyprotex's analytical work helps reduce uncertainty in early-stage drug programs and supports more efficient resource allocation, serving pharmaceutical companies, biotechnology firms, and contract research organizations that require detailed characterization of drug candidates' biological behavior.
How much funding has Cyprotex raised?
Cyprotex has raised a total of $10.8M across 1 funding round:
Debt
$10.8M
Debt (2013): $10.8M with participation from Harwood Capital
Key Investors in Cyprotex
Harwood Capital
Harwood Capital is an investment management firm specializing in public and private equities, with a focus on actively engaging in the management of its portfolio companies to generate significant returns. Their expertise likely extends to strategic growth investments in specialized sectors.
What's next for Cyprotex?
With a major enterprise-level funding context and a recent strategic investment, Cyprotex is poised for significant expansion in its preclinical analysis capabilities. This capital injection is expected to fuel advancements in its scientific services, potentially broadening its scope of evaluation for drug candidates and enhancing its analytical methodologies. The company's focus on critical early-stage drug development suggests a trajectory aimed at solidifying its position as a key partner for pharmaceutical innovation, enabling more informed decisions and efficient resource deployment in the drug pipeline.
See full Cyprotex company page
